One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester
- 1 October 2000
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 107 (10) , 1271-1275
- https://doi.org/10.1111/j.1471-0528.2000.tb11619.x
Abstract
Objective To evaluate the introduction of a one stop multidisciplinary clinic for screening for fetal chromosomal abnormalities in the first trimester by a combination of maternal serum biochemistry and ultrasonography providing a risk of chromosomal abnormalities within a one hour clinic visit. Design One year retrospective review of screening performance. Population All women attending for routine antenatal care. The population included 4190 singleton pregnancies in women of all ages screened between 10 weeks and 3 days and 13 weeks and 6 days of gestation between the periods 1 June 1998 and 31 May 1999 in a district general hospital antenatal clinic. Methods All women booked into the clinic were offered screening by a combination of maternal serum free β human chorionic gonadotrophin (hCG) and pregnancy associated plasma protein A (PAPP‐A) and fetal nuchal translucency thickness. Women at increased risk of carrying a fetus with trisomy 21 or trisomy 18/13 (≥ 1 in 300 at sampling) were offered counselling and an invasive diagnostic procedure. Follow up of the outcome of all pregnancies was carried out. Main outcome measures The detection rate for trisomy 21, trisomy 18/13 and all aneuploides, false positive rate, uptake of screening, uptake of chorionic villus sampling in women identified at increased risk and fetal loss after chorionic villus sampling. Results Overall 97.6% of the women (4088/4190) accepted first trimester screening. The rate of detection of trisomy 21 was 86% (6/7), for trisomy 18/13 100% (9/9) and for all aneuploides 95% (18/19). Fetal death at presentation was found in 1.6% of pregnancies (69/4088). Of women who accepted screening, 6.1% (257/4088) presented too late for fetal nuchal translucency measurement and 6.5% of the women (271/4088) presented too early. The false positive rate was 6.7% (253/3762). Uptake of invasive testing was 83% (207/253). Conclusion First trimester prenatal screening for chromosomal abnormalities using a combination of maternal serum biochemistry and fetal nuchal translucency thickness can achieve detection rates in excess of 90%. These services can be provided in a one stop multidisciplinary clinic.Keywords
This publication has 17 references indexed in Scilit:
- The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Screening for triploidy by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Maternal serum free ?-hCG and PAPP-A in fetal sex chromosome defects in the first trimesterPrenatal Diagnosis, 2000
- Second trimester prenatal screening for Down's syndrome using alpha‐fetoprotein and free beta hCG: a seven year reviewBJOG: An International Journal of Obstetrics and Gynaecology, 1999
- Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β -hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 1999
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999
- UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestationThe Lancet, 1998
- Antenatal Screening for Down's SyndromeJournal of Medical Screening, 1997
- Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker.BMJ, 1993
- The Mathematical Basis of Multivariate Risk Screening: With Special Reference to Screening for Down's Syndrome Associated PregnancyAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1990